Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Outlook for the Atherosclerosis Drugs Market Heading Into 2029?

The market size of atherosclerosis drugs has experienced a consistent expansion in the past few years. The expansion will continue, raising from $49.89 billion in 2024 to $50.91 billion in 2025, with a compound annual growth rate (CAGR) of 2.0%. The growth during the historical time frame is linked to factors such as cholesterol control, blood pressure management, smoking cessation initiatives, research and development, and advancements in diagnostics.

The market for atherosclerosis medications is projected to experience consistent growth in the coming years, expanding to $58.36 billion in 2029 with a compound annual growth rate of 3.5%. The growth anticipated in the forecast period can be credited to developments in emerging therapies, precision medicine, immunotherapy and inflammation, as well as advancements in lipid management and regulatory support. Significant trends to monitor in the forecast period comprise biological therapies, gene editing, gene therapies, combined treatments, individualized treatment methods, and the adoption of telemedicine and remote monitoring.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12621&type=smp

Which Factors Are Pushing The Atherosclerosis Drugs Market Forward?

The anticipated rise in cardiovascular disease cases is forecasted to enhance the atherosclerosis drug market’s growth. All diseases that could harm the heart and blood vessels are considered cardiovascular diseases, while atherosclerosis defines the accumulation of fats, cholesterol, and other substances on one’s artery walls. Atherosclerosis, notable for its plaque build-up in arteries, leads to cardiovascular ailments like stroke and coronary heart disease. Atherosclerosis drugs play a crucial role in treating cardiovascular diseases, lowering complication risks and managing associated conditions like elevated cholesterol levels and clot formation in the blood. For instance, the Minnesota Department of Health, a US-based state health agency, reported in September 2024 that around 30% or nearly 1.4 million adults in Minnesota had high blood pressure the previous year. Furthermore, in 2022, hypertensive diseases caused or contributed to nearly 28% or 14,225 of all deaths in the state. Thus, the increasing occurrence of cardiovascular diseases solidifies the surge of the atherosclerosis drug market.

Which Segment Held The Largest Share In The Atherosclerosis Drugs Market In 2025?

The atherosclerosis drugs market covered in this report is segmented –

1) By Drug Class: Anti-Platelet Medications, Fibric Acid And Omega-3 Fatty Acid Derivatives, Angiotensin-Covering Enzyme (ACE) Inhibitors, Diuretics, Cholesterol Lowering Medication, Beta Blockers, Calcium Channel Blockers, Other Drug Classes

2) By Route Of Administration: Oral, Injectable

3) By Distribution Channel: Hospital Pharmacies, Online Pharmacies, Retail Pharmacies, Other Distribution Channels

Subsegments:

1) By Anti-Platelet Medications: Aspirin, Clopidogrel, Ticagrelor

2) By Fibric Acid And Omega-3 Fatty Acid Derivatives: Fenofibrate, Gemfibrozil, Omega-3 Fatty Acid Supplements

3) By Angiotensin-Covering Enzyme (ACE) Inhibitors: Lisinopril, Enalapril, Ramipril

4) By Diuretics: Thiazide Diuretics, Loop Diuretics, Potassium-Sparing Diuretics

5) By Cholesterol Lowering Medication: Statins, PCSK9 Inhibitors, Bile Acid Sequestrants

6) By Beta Blockers: Metoprolol, Atenolol, Carvedilol

7) By Calcium Channel Blockers: Amlodipine, Diltiazem, Verapamil

8) By Other Drug Classes: Anticoagulants, Vasodilators, Cholesterol Absorption Inhibitors

How Are Key Trends Driving Expansion In The Atherosclerosis Drugs Industry?

The growing prominence of product innovation is a key trend in the atherosclerosis drugs market. Major players in this market are creating novel drugs and seeking approvals to maintain their market position. For example, in March 2024, Denmark-based healthcare giant Novo Nordisk A/S announced that Wegovy (semaglutide), one of their innovative drugs, received approval for the reduction of cardiovascular risk in overweight or obese individuals. This is the premier weight loss medication that has been approved to diminish the risk of serious cardiovascular events in adults who are obese, overweight, and have a pre-established cardiovascular disease. This medication offers a fresh treatment alternative for these individuals who are at a high-risk. Moreover, its dual functionality aids in managing obesity and preventing serious cardiovascular complications, thereby enhancing patient results and extending lives.

Which Organizations Are Driving Progress In The Atherosclerosis Drugs Industry?

Major companies operating in the atherosclerosis drugs market include Johnson And Johnson Private Limited, Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Bayer AG, Janssen Pharmaceuticals Inc., Novartis AG, Merck And Co.Inc., Sanofi S.A., AstraZeneca plc, Abbott Laboratories, GSK plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Gilead Sciences Inc., Amgen Inc., Novo Nordisk A/S, Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceutical Industries Ltd., Otsuka Holdings Co. Ltd., Regeneron Pharmaceuticals Inc., Biogen Inc., Lupin Limited, Alnylam Pharmaceuticals Inc., Ionis Pharmaceuticals Inc., Amarin Corporation plc, Esperion Therapeutics Inc., Kowa Pharmaceuticals America Inc., Anthera Pharmaceuticals Inc.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/atherosclerosis-drugs-global-market-report

Which Region Is Expected To Experience The Highest Growth In The Atherosclerosis Drugs Industry?

North America was the largest region in the atherosclerosis drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atherosclerosis drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=12621&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model